EMA Picks Valproate For First Public Hearing On Safety Of Marketed Medicines

The European Medicines Agency is re-examining the use of valproate in women to address ongoing safety concerns and will hold its first ever public hearing later this year to listen directly to the experience of EU patients with these medicines.